MN 576 Unit 10 Exam
Advanced Pathophysiology & Pharmacotherapeutics
Competency Assessment
2026/2027 Academic Year
Exact Official Question Count: 40 Multiple-Choice Questions (MCQ)
Format: Single-Best-Answer with Four Options (A, B, C, D)
Testing Time: 75 Minutes
Passing Score: 75–80% (30–32/40 Correct)
Aligned with AACN DNP Essentials & Graduate Nursing Competency Standards
Core Assessment Domains
1. Neurological & Psychopharmacology Integration (Q1–Q9)
2. Endocrine & Metabolic Pharmacotherapy (Q10–Q18)
3. Reproductive & Hormonal Therapeutics (Q19–Q24)
4. Complex Pharmacokinetic/Pharmacodynamic Principles (Q25–Q31)
5. Clinical Case Integration & Prescriptive Decision-Making (Q32–Q37)
6. Scenario-Based Clinical Judgment Application (Q38–Q40)
,Abstract
This document presents the MN 576 Unit 10 Examination for the 2026/2027 academic year,
comprising 40 multiple-choice questions aligned with graduate nursing curriculum standards for
advanced pathophysiology and pharmacotherapeutics competency assessment. The examination
covers six core domains: neurological and psychopharmacology integration, including
neurotransmitter dysregulation and antipsychotic/antidepressant/anticonvulsant pharmacology;
endocrine and metabolic pharmacotherapy, encompassing thyroid replacement, antidiabetic
agents, corticosteroid management, and diuretic-RAAS interactions; reproductive and hormonal
therapeutics, addressing contraceptive pharmacology, hormone replacement therapy, fertility
agents, and menopause management; complex pharmacokinetic and pharmacodynamic
principles, including therapeutic drug monitoring, protein binding displacement,
pharmacogenomic variability, and renal/hepatic dose adjustments; clinical case integration with
prescriptive decision-making, covering polypharmacy deprescribing, adverse drug reaction
differentiation, patient-specific dosing, and interprofessional collaboration; and scenario-based
application integrating multiple pharmacotherapeutic principles. Each question includes a
detailed rationale explaining the pharmacological mechanisms, pathophysiologic correlations,
and evidence-based rationale for the correct answer.
Keywords: MN 576, Advanced Pharmacotherapeutics, Psychopharmacology, Endocrine
Pharmacology, Pharmacokinetics, Pharmacogenomics, Therapeutic Drug Monitoring,
Polypharmacy, Graduate Nursing
Examination Instructions
• This examination consists of 40 multiple-choice questions. Select the single best answer for
each question unless otherwise indicated as Select-All-That-Apply (SATA).
• Each question has four options (A, B, C, D). Mark only one answer per question.
• The total testing time is 75 minutes. Pace yourself accordingly (approximately 1.9 minutes
per question).
• Correct answers are highlighted in bold purple (#BC13FE). Detailed rationales are provided
in italic text with a lavender background (#F5EDF9) following each question.
• A passing score of 75–80% (30–32 correct answers out of 40) is typically required per
graduate nursing program policy.
• This assessment is aligned with AACN DNP Essentials and current pharmacotherapeutic
textbook standards (Lehne, Arkles).
MN 576 Unit 10 Exam — 40 Multiple-Choice Questions
Domain 1: Neurological & Psychopharmacology Integration (Q1–Q9)
1. The mesolimbic dopamine pathway is primarily associated with which function,
and its overactivity is most linked to which clinical manifestation?
A) Motor control; Parkinsonism
B) Reward and positive reinforcement; positive symptoms of schizophrenia
C) Prolactin inhibition; galactorrhea
D) Cognitive executive function; negative symptoms of schizophrenia
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area (VTA)
to the nucleus accumbens and is the primary neural substrate for reward processing,
motivation, and positive reinforcement. Hyperactivity of this pathway is strongly associated
with the positive symptoms of schizophrenia (delusions, hallucinations, disorganized thought),
which is why D2 receptor antagonism in this pathway is the mechanistic basis for antipsychotic
efficacy. The nigrostriatal pathway (option A) governs motor control; its blockade causes EPS.
, The tuberoinfundibular pathway (option C) regulates prolactin; its blockade causes
hyperprolactinemia. The mesocortical pathway (option D) governs executive function; its
underactivity is linked to negative and cognitive symptoms.
2. A client on haloperidol develops acute dystonia 48 hours after initiation. The
nurse practitioner recognizes that this extrapyramidal symptom results from D2
receptor blockade in which pathway?
A) Mesolimbic pathway
B) Nigrostriatal pathway
C) Tuberoinfundibular pathway
D) Mesocortical pathway
Rationale: Acute dystonia (sustained, painful muscle contractions causing abnormal postures
such as torticollis, oculogyric crisis, or laryngospasm) results from D2 receptor blockade in the
nigrostriatal pathway, which connects the substantia nigra to the striatum (caudate and
putamen). This pathway normally facilitates smooth, coordinated movement through a balance
between direct (D1-mediated) and indirect (D2-mediated) pathways. D2 blockade disrupts this
balance, producing a relative cholinergic excess that manifests as acute dystonia. This EPS
typically occurs within hours to days of initiating or increasing a high-potency typical
antipsychotic and is treated with anticholinergic agents (benztropine, diphenhydramine). The
mesolimbic, tuberoinfundibular, and mesocortical pathways are not involved in motor control.
3. Atypical antipsychotics differ from typical antipsychotics primarily in their
receptor binding profile. Which receptor characteristic most distinguishes atypical
agents?
A) Pure D2 antagonism without serotonin activity
B) Combined 5-HT2A antagonism with lower-affinity D2 blockade, producing a
higher 5-HT2A/D2 binding ratio
C) Selective D1 receptor agonism
D) Muscarinic receptor agonism only
Rationale: The defining pharmacological characteristic of atypical (second-generation)
antipsychotics is their combined antagonism of serotonin 5-HT2A receptors and lower-affinity
(loose-binding) D2 receptor antagonism, resulting in a higher 5-HT2A/D2 binding ratio
compared to typical antipsychotics. The 5-HT2A blockade enhances dopaminergic
neurotransmission in the nigrostriatal pathway (reducing EPS) and the tuberoinfundibular
pathway (reducing hyperprolactinemia), while the loose D2 binding allows more rapid
dissociation from D2 receptors, which may contribute to lower EPS rates. Typical
antipsychotics are characterized by tight, high-affinity D2 blockade without significant
serotonergic activity. Neither selective D1 agonism nor muscarinic agonism defines atypical
antipsychotic pharmacology.
4. A client taking fluoxetine is prescribed tramadol. The nurse practitioner should
be most concerned about which interaction?
A) Decreased analgesic efficacy of tramadol
B) Increased risk of serotonin syndrome due to CYP2D6 inhibition and
combined serotonergic effects
C) Reduced fluoxetine efficacy via CYP3A4 induction
D) Increased risk of QT prolongation only
Rationale: Fluoxetine is a potent CYP2D6 inhibitor that blocks the O-demethylation of tramadol
to its more active M1 metabolite (which has mu-opioid agonist activity). However, the greater
concern is the combined serotonergic effect: fluoxetine inhibits serotonin reuptake, and
Advanced Pathophysiology & Pharmacotherapeutics
Competency Assessment
2026/2027 Academic Year
Exact Official Question Count: 40 Multiple-Choice Questions (MCQ)
Format: Single-Best-Answer with Four Options (A, B, C, D)
Testing Time: 75 Minutes
Passing Score: 75–80% (30–32/40 Correct)
Aligned with AACN DNP Essentials & Graduate Nursing Competency Standards
Core Assessment Domains
1. Neurological & Psychopharmacology Integration (Q1–Q9)
2. Endocrine & Metabolic Pharmacotherapy (Q10–Q18)
3. Reproductive & Hormonal Therapeutics (Q19–Q24)
4. Complex Pharmacokinetic/Pharmacodynamic Principles (Q25–Q31)
5. Clinical Case Integration & Prescriptive Decision-Making (Q32–Q37)
6. Scenario-Based Clinical Judgment Application (Q38–Q40)
,Abstract
This document presents the MN 576 Unit 10 Examination for the 2026/2027 academic year,
comprising 40 multiple-choice questions aligned with graduate nursing curriculum standards for
advanced pathophysiology and pharmacotherapeutics competency assessment. The examination
covers six core domains: neurological and psychopharmacology integration, including
neurotransmitter dysregulation and antipsychotic/antidepressant/anticonvulsant pharmacology;
endocrine and metabolic pharmacotherapy, encompassing thyroid replacement, antidiabetic
agents, corticosteroid management, and diuretic-RAAS interactions; reproductive and hormonal
therapeutics, addressing contraceptive pharmacology, hormone replacement therapy, fertility
agents, and menopause management; complex pharmacokinetic and pharmacodynamic
principles, including therapeutic drug monitoring, protein binding displacement,
pharmacogenomic variability, and renal/hepatic dose adjustments; clinical case integration with
prescriptive decision-making, covering polypharmacy deprescribing, adverse drug reaction
differentiation, patient-specific dosing, and interprofessional collaboration; and scenario-based
application integrating multiple pharmacotherapeutic principles. Each question includes a
detailed rationale explaining the pharmacological mechanisms, pathophysiologic correlations,
and evidence-based rationale for the correct answer.
Keywords: MN 576, Advanced Pharmacotherapeutics, Psychopharmacology, Endocrine
Pharmacology, Pharmacokinetics, Pharmacogenomics, Therapeutic Drug Monitoring,
Polypharmacy, Graduate Nursing
Examination Instructions
• This examination consists of 40 multiple-choice questions. Select the single best answer for
each question unless otherwise indicated as Select-All-That-Apply (SATA).
• Each question has four options (A, B, C, D). Mark only one answer per question.
• The total testing time is 75 minutes. Pace yourself accordingly (approximately 1.9 minutes
per question).
• Correct answers are highlighted in bold purple (#BC13FE). Detailed rationales are provided
in italic text with a lavender background (#F5EDF9) following each question.
• A passing score of 75–80% (30–32 correct answers out of 40) is typically required per
graduate nursing program policy.
• This assessment is aligned with AACN DNP Essentials and current pharmacotherapeutic
textbook standards (Lehne, Arkles).
MN 576 Unit 10 Exam — 40 Multiple-Choice Questions
Domain 1: Neurological & Psychopharmacology Integration (Q1–Q9)
1. The mesolimbic dopamine pathway is primarily associated with which function,
and its overactivity is most linked to which clinical manifestation?
A) Motor control; Parkinsonism
B) Reward and positive reinforcement; positive symptoms of schizophrenia
C) Prolactin inhibition; galactorrhea
D) Cognitive executive function; negative symptoms of schizophrenia
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area (VTA)
to the nucleus accumbens and is the primary neural substrate for reward processing,
motivation, and positive reinforcement. Hyperactivity of this pathway is strongly associated
with the positive symptoms of schizophrenia (delusions, hallucinations, disorganized thought),
which is why D2 receptor antagonism in this pathway is the mechanistic basis for antipsychotic
efficacy. The nigrostriatal pathway (option A) governs motor control; its blockade causes EPS.
, The tuberoinfundibular pathway (option C) regulates prolactin; its blockade causes
hyperprolactinemia. The mesocortical pathway (option D) governs executive function; its
underactivity is linked to negative and cognitive symptoms.
2. A client on haloperidol develops acute dystonia 48 hours after initiation. The
nurse practitioner recognizes that this extrapyramidal symptom results from D2
receptor blockade in which pathway?
A) Mesolimbic pathway
B) Nigrostriatal pathway
C) Tuberoinfundibular pathway
D) Mesocortical pathway
Rationale: Acute dystonia (sustained, painful muscle contractions causing abnormal postures
such as torticollis, oculogyric crisis, or laryngospasm) results from D2 receptor blockade in the
nigrostriatal pathway, which connects the substantia nigra to the striatum (caudate and
putamen). This pathway normally facilitates smooth, coordinated movement through a balance
between direct (D1-mediated) and indirect (D2-mediated) pathways. D2 blockade disrupts this
balance, producing a relative cholinergic excess that manifests as acute dystonia. This EPS
typically occurs within hours to days of initiating or increasing a high-potency typical
antipsychotic and is treated with anticholinergic agents (benztropine, diphenhydramine). The
mesolimbic, tuberoinfundibular, and mesocortical pathways are not involved in motor control.
3. Atypical antipsychotics differ from typical antipsychotics primarily in their
receptor binding profile. Which receptor characteristic most distinguishes atypical
agents?
A) Pure D2 antagonism without serotonin activity
B) Combined 5-HT2A antagonism with lower-affinity D2 blockade, producing a
higher 5-HT2A/D2 binding ratio
C) Selective D1 receptor agonism
D) Muscarinic receptor agonism only
Rationale: The defining pharmacological characteristic of atypical (second-generation)
antipsychotics is their combined antagonism of serotonin 5-HT2A receptors and lower-affinity
(loose-binding) D2 receptor antagonism, resulting in a higher 5-HT2A/D2 binding ratio
compared to typical antipsychotics. The 5-HT2A blockade enhances dopaminergic
neurotransmission in the nigrostriatal pathway (reducing EPS) and the tuberoinfundibular
pathway (reducing hyperprolactinemia), while the loose D2 binding allows more rapid
dissociation from D2 receptors, which may contribute to lower EPS rates. Typical
antipsychotics are characterized by tight, high-affinity D2 blockade without significant
serotonergic activity. Neither selective D1 agonism nor muscarinic agonism defines atypical
antipsychotic pharmacology.
4. A client taking fluoxetine is prescribed tramadol. The nurse practitioner should
be most concerned about which interaction?
A) Decreased analgesic efficacy of tramadol
B) Increased risk of serotonin syndrome due to CYP2D6 inhibition and
combined serotonergic effects
C) Reduced fluoxetine efficacy via CYP3A4 induction
D) Increased risk of QT prolongation only
Rationale: Fluoxetine is a potent CYP2D6 inhibitor that blocks the O-demethylation of tramadol
to its more active M1 metabolite (which has mu-opioid agonist activity). However, the greater
concern is the combined serotonergic effect: fluoxetine inhibits serotonin reuptake, and
